Market Overview

UPDATE: Goldman Sachs Upgrades Stryker Corporation to Buy on Organic Growth, Capital Allocation

Share:
Related SYK
FDA's 60-Day Extension For Medical Device Defects Not Likely Obstructive To Public Health
Benzinga's Top Upgrades, Downgrades For June 30, 2017
State Treasurer State Of Michigan Buys CVS Health Corp, Square Inc, AGNC Investment Corp, Sells ... (GuruFocus)

Goldman Sachs raised its rating on Stryker Corporation (NYSE: SYK) from Neutral to Buy and increased its price target from $55 to $68.

Goldman Sachs noted, "Our thesis calls for improvements in both operational and financial performance as follows: (1) new CEO and a reset of expectations for 2013; (2) strong product portfolio/pipeline and diversified revenue base offer multiple growth opportunities; (3) shareholder-friendly capital allocation with a greater orientation to cash returns; (4) cost and quality control initiatives remain a source of margin opportunity; and (5) attractive relative valuation compared to other large-cap MedTech firms in our coverage universe."

Stryker Corporation closed at $54.57 on Monday.

Latest Ratings for SYK

DateFirmActionFromTo
Jun 2017Cantor FitzgeraldInitiates Coverage OnNeutral
May 2017Goldman SachsInitiates Coverage OnNeutral
Dec 2016UBSUpgradesNeutralBuy

View More Analyst Ratings for SYK
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (SYK)

View Comments and Join the Discussion!